NIFFENEGGER KATHI 4
4 · Stellar Biotechnologies, Inc. · Filed Mar 14, 2018
Insider Transaction Report
Form 4
NIFFENEGGER KATHI
Chief Financial Officer
Transactions
- Award
Share Option (Right to Buy)
2018-03-12+35,000→ 35,000 totalExercise: $0.84Exp: 2025-03-12→ Common Shares (35,000 underlying)
Footnotes (1)
- [F1]Option grant under the 2017 Incentive Compensation Plan, which shall vest as to one-third immediately, as to one-third on March 12, 2019 and as to the remaining one-third on September 12, 2019.